HOOKIPA Pharma, Inc. (HOOK) | Stock price, performance, AI analysis | Thematic | AI powered fundamental research and development platform

Company performance

Add to research

Current Price

as of Jun 18, 2025

$1.30

P/E Ratio

N/A

Market Cap

$15.92M

Description

Add to research

HOOKIPA Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in developing pharmaceutical products to prevent and cure infectious diseases and cancer. It also focuses on immunotherapeutics based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. The company was founded by Rolf M. Zinkernagel, Andreas Bergthaler, Lukas Flatz, and Daniel D. Pinschewer in 2011 and is headquartered in New York, NY.

Metrics

Add to research

Overview

HQNew York, NY
SectorHealth Technology
IndustryBiotechnology
TickerHOOK
Price$1.305-0.38%

Trading Information

Market cap$15.92M
Float57.25%
Average Daily Volume (1m)173,412
Average Daily Volume (3m)121,140
EPS-$5.93

Company

Revenue$9.35M
Rev growth (1yr)-94.52%
Net income-$15.43M
Gross margin80.59%
EBITDA margin-865.87%
EBITDA-$17.35M

EV-$26.23M
EV/Revenue-2.81
P/EN/A
P/S1.75
P/B0.46
Debt/Equity1.75

Documents

Add to research

Earnings Calls

Earnings Report 2022Q4

Earnings Report (2023-03-15)

Factset

Factset Business Description

Factset Street Account

Hookipa Pharma reports Q3 EPS ($0.17) vs FactSet ($0.21) [6 est, ($0.26)-(0.16)] ($0.50, 0.00) (2023-11-09T12:11:32Z)

Hookipa Pharma presents positive Biomarker and translational data on HB-200 monotherapy at SITC 2023 ($0.45, +0.02) (2023-11-03T16:05:21Z)

HOOKIPA Pharma presents additional preliminary Phase 2 data on HB-200 in combination with pembrolizumab as first-line treatment in patients with HPV16+ head and neck cancers at ESMO ($0.47, 0.00) (2023-10-22T15:18:57Z)

HOOKIPA Pharma announces publication of preclinical data of hepatitis B virus (HBV) therapeutic vaccine developed in collaboration with Gilead Sciences (GILD) ($0.52, 0.00) (2023-10-18T11:05:30Z)

HOOKIPA Pharma announces FDA clearance of IND application for HB-500 for treatment of human immunodeficiency virus ($0.52, 0.00) (2023-11-20T12:03:39Z)